BCL6 and lymphoma: While HGBCL-DH-BCL6 lymphomas appear molecularly and prognostically heterogeneous [24, 26, 30, 33–36, 38, 39], potential distinct clinico-biologic correlates of “pseudo-double hit” BCL remain poorly studied [36, 40, 41].